
Figure 1A

Compound A + lenalidomide



Compound A + pomalidomide





Figure 1B

Compound B + lenalidomide



Compound B + pomalidomide





Figure 1C

Compound C + lenalidomide



Compound C + pomalidomide




Figure 1D





Figure 1E

Compound B + lenalidomide



Compound B + pomalidomide





Figure 1F

Compound C + lenalidomide



Compound C + pomalidomide






Figure 2

A


100
80
60
40
20
0
% of Cells
G2
S
G1
Sub G1
Compound B (μM) - 1 - 1 - 1
Lenalidomide (μM) - - 2 2 - -
Pomalidomide (μM) - - - - 1 1

B


100
80
60
40
20
0
% of Cells
G2
S
G1
Sub G1
Compound A (μM) - 2 - 2 - 2
Lenalidomide (μM) - - 2 2 - -
Pomalidomide (μM) - - - - 1 1

C




100
80
60
40
20
0
% of Cells
G2
S
G1
Sub G1
Compound B (μM) - 2 - 2 - 2
Lenalidomide (μM) - - 2 2 - -
Pomalidomide (μM) - - - - 1 1

Figure 3

A


100
75
50
40
20
0
% of Cells
Live
Early Apoptosis
Late Apoptosis
Dead
Compound A (μM) - 2 - 2 - 2
Lenalidomide (μM) - - 2 2 - -
Pomalidomide (μM) - - - - 1 1

B




100
80
60
40
20
0
% of Cells
Live
Early Apoptosis
Late Apoptosis
Dead
Compound B (μM) - 2 - 2
Pomalidomide (μM) - - 1 1

Figure 4


DMSO
2 µM Compound A
3 µM Compound A
Pom
2 µM Compound A + Pom
3 µM Compound A + Pom
MYC
IRF4
IKZF3
PARP
Ac-α-Tubulin
β-Actin